Neldam Steen, Edwards Colin
Rødovre Centrum, Denmark.
J Clin Hypertens (Greenwich). 2008 Aug;10(8):612-8. doi: 10.1111/j.1751-7176.2008.08187.x.
This study examined the effects of increasing the thiazide diuretic dose in a fixed-dose ARB/diuretic combination in patients with uncontrolled hypertension despite 6 weeks' open-label treatment with the ARB/diuretic combination, telmisartan 80 mg/hydrochlorothiazide 12.5 mg (T80/H12.5). 713 patients with trough seated DBP =90 mmHg were then randomized to 8 weeks' double-blind treatment with telmisartan 80 mg and an increased dose of 25 mg of hydrochlorothiazide (T80/H25) or T80/H12.5. Adjusted mean seated DBP changes from baselines of 95.3 (T80/H25) and 95.0 mmHg (T80/H12.5) were -7.1 and --5.5 mmHg (difference: 1.6 mm Hg), respectively (P=.0012). Changes in systolic blood pressure from 147.9 mmHg (T80/H25) and 147.4 mmHg (T80/H12.5) were -9.8 and -7.1 mmHg (difference: 2.7 mm Hg) (P=.0003). Adverse events occurred in 31.5% (T80/H25) and 29.6% (T80/H12.5), with serious events in 1.4% and 0.8%, respectively. Hypokalemia was rare. These results show that higher-dose thiazide diuretic in combination with T80 in patients with hypertension uncontrolled by T80/H12.5 provides additional blood pressure reductions and is well tolerated.
本研究探讨了在使用固定剂量的血管紧张素Ⅱ受体拮抗剂(ARB)/利尿剂联合治疗6周后血压仍未得到控制的患者中,增加噻嗪类利尿剂剂量的效果。这6周的开放标签治疗使用的是ARB/利尿剂联合制剂替米沙坦80毫克/氢氯噻嗪12.5毫克(T80/H12.5)。然后,713例谷值坐位舒张压(DBP)=90 mmHg的患者被随机分配接受为期8周的双盲治疗,一组使用替米沙坦80毫克和增加至25毫克的氢氯噻嗪(T80/H25),另一组使用T80/H12.5。从基线95.3(T80/H25)和95.0 mmHg(T80/H12.5)调整后的平均坐位DBP变化分别为-7.1和-5.5 mmHg(差值:1.6 mmHg)(P = 0.0012)。收缩压从147.9 mmHg(T80/H25)和147.4 mmHg(T80/Hl2.5)的变化分别为-9.8和-7.1 mmHg(差值:2.7 mmHg)(P = 0.0003)。不良事件发生率在T80/H25组为31.5%,在T80/H12.5组为29.6%,严重不良事件发生率分别为1.4%和0.8%。低钾血症很少见。这些结果表明,对于使用T80/H12.5未能控制血压的高血压患者,更高剂量的噻嗪类利尿剂与T80联合使用可进一步降低血压,且耐受性良好。